NCT01488565 - A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2015

Conditions

Myelodysplastic Syndromes (MDS)Acute Myeloid Leukaemia (AML)

Interventions

DRUG

Azacitidine and eltrombopag

Standard: azacitidine D1-5, 8\&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.

Trial Locations (2)

3002

Peter MacCallum Cancer Centre, East Melbourne

3144

Cabrini Hospital, Malvern